Interferon beta (IFN-β) is now established as an effective maintenance therapy for multiple sclerosis (MS) that can both slow disease progression and reduce clinical exacerbations. [1] [2] [3] [4] [5] [6] Studies have demonstrated that the three widely used IFN-βa formulations -IFN-β1b 250µg (8MIU) by subcutaneous (SC) injection every other day (EOD; Betaferon ® , Bayer Schering Pharma); IFN-β1a 44µg (12MIU) by SC injection three times per week (Rebif ® , Merck Serono); and IFN-β1a 30µg (6MIU) by intramuscular (IM) injection once per week (Avonex ® , Biogen Idec) -all offer acceptable tolerability and safety profiles. 7, 8 Data suggest that the two higher-dose, more frequent formulations (Betaferon and Rebif) offer better efficacy than the lower-dose, less frequent Avonex. 7-9 Adverse events (AEs) are reported to be similar across all three formulations. 7, 8 However, according to one comparative study there may be an increase in headaches and injection-site reactions (ISRs) with higher-dose SC formulations compared with lower-dose IM However, this study pre-dated the development of new SC injector technology that is likely to influence ISRs. Injection-site pain (ISP) and ISRs are a common concern with injectable therapies and can impair adherence to treatment and potentially contribute to discontinuation of therapy. 7, 8, 10 This article reviews evidence on factors influencing ISRs, ISP and adherence, and presents the results of patient and nurse surveys on a new IFN-β auto-injector.
high-frequency IFN-β formulations, in addition to the benefits of reducing needle thickness. 15, 16 The BRIGHT Study
The BRIGHT study was the first large-scale comparison of ISRs and ISP in patients with RRMS using 250µg IFN-β1b EOD versus 44µg (2004/2005 formulation of Rebif) three times a week. Patients enrolled into the study had been previously treated with IFN-β for at least one month but not more than three months and had completed the dosetitration phase of their treatment. 15 Within the study observation time of four to five weeks, patients injected 15 consecutive doses of their prescribed IFN formulation and rated their ISP on a visual analogue scale (VAS) immediately, 30 minutes and 60 minutes after each injection. The main study outcome was the proportion of patients who were pain-free at all three timepoints after each injection. The study nurse telephoned patients each week to check for AEs, wellbeing and correct VAS diary. At the end of the study, patients assessed the impact of pain on overall treatment satisfaction and ease of auto-injector use (where applicable). The study nurse assessed ISR occurrence and severity at both the beginning and the end of the study. Other end-of-study measures included disease status, AEs and concomitant medication.
A total of 454 patients (306 on Betaferon and 148 on Rebif) entered the study at 76 centres in 13 countries. Reported outcomes were based on the valid case (VC) population of 445 patients (303 on Betaferon and 142 on Rebif), which excluded patients who either used a reduced IFN-β dose at least once or completed their VAS diary incorrectly.
Baseline demographics and MS duration, status and disease characteristics were broadly similar in the two treatment groups.
There were significantly higher proportions of pain-free patients and pain-free injections per patient at all time-points on Betaferon than on Rebif (p<0.0001) (see Figures 1 and 2) . Similarly, mean VAS scores were lower (p<0.0001) for patients using Betaferon compared with Rebif at all time-points and across all injections. ISRs were also significantly more common in the Rebif group than in the Betaferon group (p=0.0184 and p<0.001 at visits 1 and 2, respectively).
It is reasonable to predict that reducing pain and ISRs would encourage patient adherence. This is consistent with the result that significantly more patients who injected Rebif than who received Betaferon reported that pain had negatively affected their satisfaction with treatment (p=0.006). A smaller needle gauge is also likely to promote adherence; this study was not powered to detect a difference in pain according to needle size, but did show a non-significant trend for fewer pain-free injections with a smaller-diameter needle. In a post hoc sub-analysis, more patients were pain-free using the thinner 30-gauge needle at the 60 minutes post-injection time-point over all 15 injections (75.0% versus 52.2% with the 27-gauge needle; p=0.0086). 17 
The REFORM Study
More recent data on the comparative tolerability of IFN-β1a and IFN-β1b are available from the REFORM study, 18 which was a multicentre, randomised, open-label comparison of the two treatments over 12 weeks. Two groups of treatment-naïve patients with RRMS who were balanced for baseline demographic and disease parameters received either IFN-β1a 44ug SC three times weekly (n=65) or IFN-β1b 250ug SC every other day (n=64).
In this study, compliance was high on both treatments. There was a higher frequency of ISR with IFN-β1a compared with IFNβ1b (29.2 and 14.1%, respectively), but the rates of ISP were similar in both groups (6.2 and 6.3%, respectively). The indicence of adverse events was mostly similar for the two groups, and within the ranges and of the types expected for these medications. However, the incidence of increased alanine aminotransferase (ALT), nausea, urinary tract infection, increased serum ferritin, chills, influenza, injection-site bruising and abnormal liver function tests (LFT) were higher with IFN-β1a than with IFN-β1b. The REFORM study therefore showed essential similarity in the tolerability profiles of Rebif new Improving Patient Satisfaction with Injection Devices in Multiple Sclerosis Improves Adherence Betaferon ® 250µg Baum et al., 2007. 15 formulation and Betaferon; an extension to the study will show whether there are any long-term advantages of either treatment in terms of tolerability.
A significantly higher mean percentage of patients had pain-free injections on Betaferon than on Rebif at all time-points (p<0.0001). Source:

The Evolving Role of the Nurse in Multiple Sclerosis
Regular nursing support is a key element in MS management. The role of the specialist MS nurse has grown with the increasing complexity of treatment; the widespread introduction of INF-β as a disease-modifying therapy has contributed to this expanding role. 19, 20 According to a recently published survey, patients with MS consider information and education about MS and its treatment to be especially important elements of their nursing care. 21 showed that use of a specialist nurse programme or a patient education website resulted in the most pronounced increase in patient QoL during the analysed time-frame. 22 Recent data from the BENEFIT trial may have important implications for nursing care in MS. 14, 23, 24 This study revealed reductions in MS progression when patients received 250µg Betaferon EOD after their first clinical demyelinating event, with a 50% risk reduction for progression to clinically definite MS (CDMS) after two years on Betaferon compared with placebo or delayed treatment. 14 At threeand five-year active-treatment follow-up, early Betaferon treatment was linked with a 41 and 37% reduction, respectively, in the risk of progression to CDMS compared with delayed Betaferon treatment. 22, 23 Earlier placebo-controlled studies using various treatments and dosing schedules have also shown the value of early immunomodulatory treatment in delaying conversion to CDMS.
14, [25] [26] [27] What does this mean for nursing care in MS? The results support early treatment with IFN-β. Increased prescribing in early MS could add a growing population of relatively well patients to the nurse's caseload.
Supporting adherence to treatment in early MS or in patients with a first event suggestive of MS may represent a particular challenge with these patients.
Promoting Patient Adherence
Adherence is crucial to optimise treatment efficacy and hence patient As of 2004, the BETA Nurse programme had recruited over 10,000 patients, and only 1.6% had been lost to follow-up. 37 Support and advice on simple techniques, such as starting Betaferon on a reduced dose and gradually increasing to the full dose, using an auto-injector, rotating injection sites and using concomitant treatment such as ibuprofen or paracetamol as prescribed to reduce influenza-like symptoms, have been linked with excellent adherence. Only 0.8% of patients discontinued due to ISRs, 2.1% due to influenza-like symptoms and 1.7% for perceived lack of efficacy.
Treatment Acceptability
The BENEFIT study incorporated several measures to optimise treatment acceptability, consistent with the advice patients receive on the BETA Nurse programme. 14,37 Participants used auto-injector devices (if approved in their country) to reduce ISRs, and received paracetamol or ibuprofen to minimise influenza-like symptoms during the first three months of treatment. 14 The dose was also titrated from an initial 62.5µg, increasing by 62.5µg every fourth injection up to the full 250µg dose. Over 97% of patients in both the Betaferon and placebo groups received at least 80% of scheduled doses, and 96% of both groups chose to receive Betaferon in the extension study. The difference with the thinner 55 (77) 77 (90) 132 (85) needle is less pain; n (% of respondents who felt a difference)
Multiple Sclerosis reduced needle size (27-30G). In addition, a hidden needle system can help to overcome needle phobia, and an audible signal indicates when the injector can be safely withdrawn. 42 Most patients in Italy and Spain (71%) rated Betaject Comfort as less painful than previous injection systems (see Table 1 ), while 94% of French respondents were either 'satisfied' or 'very satisfied' with the level of pain induced by Betaject Comfort. Interestingly, more than two-thirds of Italian and Spanish patients (68%) said that they could feel a difference using the new, thinner needle, of whom 85% described this difference as reduced pain compared with their older injection systems (see Table 1 ). Patients also linked the new autoinjector with reduced ISRs: 70% of Spanish respondents said that they experienced fewer ISRs with the thinner needle, and in Italy 46% of patients thought (based on personal experience) that the new injection system would cause fewer ISRs than previous systems (46% commented that they did not have any ISRs). Over one-third of Italian respondents (35%) said that the new system encouraged better adherence than previous injection systems. 42 Having an invisible needle was viewed positively by about 90% and 81% of French and Italian respondents, respectively. The needle withdrawal system was also popular with patients: 89% of Spanish and 100% of both Italian and French respondents rated it as satisfactory or better. 42 In the Italian survey, 69% of patients considered the new system to be more practical than previous systems. Practical benefits included ease of use, ease of remembering operating steps, reliability, comfort, practicality and speed of preparation ('easier' or 'much easier' to use: 62%; 'easier' or 'much easier' to remember steps: 59%; 'more reliable' or 'much more reliable': 59%; 'more comfortable' or 'much more comfortable': 74%; 'more practical' or 'much more practical': 88%;
'faster' or 'much faster' to prepare: 56%). Most patients also said that the new adaptor was more comfortable, simpler and more manageable than previous systems (88, 80 and 65%, respectively).
Most Spanish respondents (82%) rated the Betaject Comfort easier to access and inject different parts of the body, which may encourage injection-site rotation. The Spanish survey also found that patients rated the new pre-attached needle more (40%) or much more convenient (30%), while 79% reported that the pre-attached needle simplified the process. Improving Patient Satisfaction with Injection Devices in Multiple Sclerosis Improves Adherence A sample including 20-25% of all specialist MS nurses in the UK (n=48) returned similar comments on the Betaject Comfort.
Satisfaction was also high with the two most important features of an auto-injector (according to respondents; see Table 2 ), ease of holding and ease of firing (about 89 and 93%, respectively). About 90% or more of nurses considered the Betaject Comfort to be an improvement over previous models in terms of ease of holding and firing (see Table 3 ), with 94% of the nurses agreeing that, overall, the Betaject Comfort was an improvement over older Betaject models.
These results correlate well with feedback from French patients with MS, over 80% of whom were satisfied or very satisfied with the Betaject Comfort's ease of handling. Similarly, needle withdrawal was highly rated by patients and ranked as the third most important feature by MS nurses. 42 Over 70% of nurses were 'totally satisfied' and nearly 20% were 'satisfied' with the Betaject Comfort's hidden needle, which also gained positive feedback from 80-90% of patients. Nurses also commented that the new system was good for needle phobia and for hard-to-reach areas, and that it reduced bruising. These factors are all likely to promote adherence; indeed, several of the nurses surveyed volunteered the comment that the Betaject Comfort 'improves adherence'.
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Summary and Conclusions
Recent data suggest that adherence to a programme of IFN-β from the first demyelinating event can delay progression to CDMS and reduce relapses in MS. The tolerability and safety profiles of all three widely used formulations are generally good. Variations in efficacy and tolerability appear to be related to dose, formulation and mode of delivery.
Adherence is a major concern even with oral therapies, and injectable treatments such as IFN-β carry their own issues, notably ISRs, ISP and injection anxiety. Strategies that improve treatment acceptability and/or patient support are likely to promote good adherence and thus optimise treatment efficacy. These include:
• considering patient type when selecting an appropriate IFN-β;
• using an auto-injector whenever possible -this reduces pain compared with manual injection, and features such as a hidden needle may help alleviate injection anxiety; and
• ensuring that all patients with MS receive regular nursing support, to include education (including realistic efficacy expectations) and injection training, not only at the beginning of therapy but also throughout life.
New injection technologies such as the Betaject Comfort offer improved ease of use and reduced pain and ISRs compared with earlier auto-injectors. Surveys in four European countries indicate that both MS nurses and patients rate the Betaject Comfort system as an improvement over previous models that may enhance adherence.
In conclusion, it seems that a dual approach of optimising treatment acceptability through formulation and injector design and providing ongoing patient education and nursing support can increase adherence to injectable therapies, in both MS and other chronic conditions. n
